KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Exchange Rate Effect (2016 - 2026)

Gsk has reported Exchange Rate Effect over the past 18 years, most recently at $2.7 million for Q1 2026.

  • For Q1 2026, Exchange Rate Effect rose 119.46% year-over-year to $2.7 million; the TTM value through Mar 2026 reached -$100.3 million, up 44.81%, while the annual FY2025 figure was -$25.3 million, 63.54% up from the prior year.
  • Exchange Rate Effect for Q1 2026 was $2.7 million at Gsk, up from -$54.5 million in the prior quarter.
  • Over five years, Exchange Rate Effect peaked at $97.4 million in Q4 2022 and troughed at -$109.2 million in Q4 2023.
  • A 5-year average of -$17.5 million and a median of -$24.1 million in 2024 define the central range for Exchange Rate Effect.
  • Biggest five-year swings in Exchange Rate Effect: soared 312.41% in 2022 and later crashed 334.01% in 2023.
  • Year by year, Exchange Rate Effect stood at $97.4 million in 2022, then crashed by 212.19% to -$109.2 million in 2023, then skyrocketed by 68.27% to -$34.7 million in 2024, then tumbled by 57.37% to -$54.5 million in 2025, then surged by 104.94% to $2.7 million in 2026.
  • Business Quant data shows Exchange Rate Effect for GSK at $2.7 million in Q1 2026, -$54.5 million in Q4 2025, and -$13.9 million in Q1 2025.